FGF19, fibroblast growth factor 19, 9965

N. diseases: 123; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease 		0.030 AlteredExpression disease BEFREE NASH was independently associated with both FXR protein levels (OR = 0.18, 95% CI 0.09, 0.38) and FGF19 concentration (OR = 0.55, 95% CI 0.20, 0.89). 28746779 2018
CUI: C1512409
Disease: Hepatocarcinogenesis
Hepatocarcinogenesis 		0.080 Biomarker disease BEFREE FGF19 is a recently identified driver gene in hepatocarcinogenesis and an activator of β-catenin signaling in HCC and colon cancer cells. 23285165 2012
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.070 AlteredExpression phenotype BEFREE FGF19 silencing in prostate cancer cells expressing autocrine FGF19 decreased invasion and proliferation in vitro and tumor growth in vivo. 23440425 2013
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE FGF19 silencing in prostate cancer cells expressing autocrine FGF19 decreased invasion and proliferation in vitro and tumor growth in vivo. 23440425 2013
CUI: C1623038
Disease: Cirrhosis
Cirrhosis 		0.010 GeneticVariation disease BEFREE FGF19 amplifications, known to activate Wnt signaling, were mutually exclusive with CTNNB1 and AXIN1 mutations, and significantly associated with cirrhosis (P = 0.017). 24798001 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.400 AlteredExpression disease BEFREE FGF19 is overexpressed in a significant proportion of human hepatocellular carcinomas (HCC), and activation of its receptor FGFR4 promotes HCC cell growth. 25346390 2015
CUI: C0023895
Disease: Liver diseases
Liver diseases 		0.030 Biomarker group BEFREE FGF19 correlates with severity of liver disease and can potentially serve as an indicator of chronic cholestatic liver injury. 26293907 2015
CUI: C0206698
Disease: Cholangiocarcinoma
Cholangiocarcinoma 		0.010 Biomarker disease BEFREE FGF19 has been shown to be involved in EMT in cholangiocarcinoma and colorectal cancer, however, molecular mechanisms underlying FGF19-induced EMT process in hepatocellular carcinoma (HCC) remain largely unknown. 26498355 2016
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.010 Biomarker disease BEFREE FGF19 has been shown to be involved in EMT in cholangiocarcinoma and colorectal cancer, however, molecular mechanisms underlying FGF19-induced EMT process in hepatocellular carcinoma (HCC) remain largely unknown. 26498355 2016
CUI: C4722085
Disease: Malignant neoplasm of colon and/or rectum
Malignant neoplasm of colon and/or rectum 		0.010 Biomarker disease BEFREE FGF19 has been shown to be involved in EMT in cholangiocarcinoma and colorectal cancer, however, molecular mechanisms underlying FGF19-induced EMT process in hepatocellular carcinoma (HCC) remain largely unknown. 26498355 2016
CUI: C4524087
Disease: Bile acid diarrhea
Bile acid diarrhea 		0.070 Biomarker disease BEFREE FGF19 profiles in PBAD patients included low fasting and meal-stimulated responses, which were both strongly correlated with SeHCAT. 26856750 2016
CUI: C0028754
Disease: Obesity
Obesity 		0.100 Biomarker disease BEFREE FGF19 and FGF21 function as endocrine hormones that play key roles in energy metabolism and counteract obesity. 27125742 2016
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.100 Biomarker disease BEFREE FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss. 27188262 2017
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X 		0.220 Biomarker disease BEFREE FGF19 is a promising therapeutic target for the metabolic syndrome and cholestatic diseases, but enthusiasm for its use has been tempered by FGF19-mediated induction of proliferation and hepatocellular carcinoma. 28178326 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.400 Biomarker disease BEFREE FGF19 is a promising therapeutic target for the metabolic syndrome and cholestatic diseases, but enthusiasm for its use has been tempered by FGF19-mediated induction of proliferation and hepatocellular carcinoma. 28178326 2017
CUI: C0007137
Disease: Squamous cell carcinoma
Squamous cell carcinoma 		0.020 Biomarker disease BEFREE FGF19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas. 28906590 2017
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.010 AlteredExpression group BEFREE FGF19 is particularly highly expressed in luminal molecular subtype of breast tumors and its expression levels are positively associated with its secretion levels from breast cancer cells. 30074276 2018
CUI: C0853897
Disease: Diabetic Cardiomyopathies
Diabetic Cardiomyopathies 		0.020 Biomarker disease BEFREE Fibroblast growth factor 19 (FGF19) acts as a metabolic regulator and may have a cardioprotective role on diabetic cardiomyopathy. 30243718 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE Fibroblast growth factor 19 (FGF19) promotes tumor growth in various types of cancer, but its function has not been investigated in the context of colorectal adenoma. 30517925 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 Biomarker group BEFREE Fibroblast growth factor 19 (FGF19) promotes tumor growth in various types of cancer, but its function has not been investigated in the context of colorectal adenoma. 30517925 2019
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon 		0.030 AlteredExpression disease BEFREE FGF19 expression was also elevated in a subset of human colon cancer cell lines. 30517925 2019
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.030 AlteredExpression disease BEFREE FGF19 expression was also elevated in a subset of human colon cancer cell lines. 30517925 2019
CUI: C1168401
Disease: Squamous cell carcinoma of the head and neck
Squamous cell carcinoma of the head and neck 		0.010 Biomarker disease BEFREE FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma. 30518874 2019
CUI: C0400966
Disease: Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease 		0.100 Biomarker disease BEFREE FGF19 negatively correlated with C4 (rs = -0.43, p = 0.001) and with alanine aminotransferase (rs = -0.22, p = 0.03), but not with either NAFLD fibrosis or Fibroscan scores. 30682184 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.060 Biomarker disease BEFREE FGF19-based drugs reduce steatosis in patients with NASH, and ameliorate bile acid-induced liver damage in patients with cholestasis. 30893110 2019